Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
| 15.86 | |
| 14.9 | |
| - | |
| 15.97 | |
| 14.785 | |
| 3.35-17.58 | |
| 759 M | |
| 52 121 K | |
| 7 844 K | |
| -0.57 | |
| 0.863 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
BEDFORD, Mass., January 17, 2024--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prot...
Shares of Amarin Corporation plc AMRN surged 32.8% on Jan 10 after the company announced robust preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a shar...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
